Zoledronic Acid for Prevention of Fractures in Parkinson’s Disease and Parkinsonism

What is the Purpose of this Study?

The purpose of this study is to determine whether a medicine called zoledronic acid can reduce fractures in people with Parkinson's disease or parkinsonism. People with Parkinson's disease or parkinsonism have a high risk of fractures related to falls. Zoledronic acid is approved by the U.S. Food and Drug Administration (FDA) for osteoporosis (weak bones); its use in this study is experimental. Participants will be randomly assigned to 1 of 2 study groups. Group 1 will receive a placebo (substance without medicine); Group 2 will receive zoledronic acid via infusion. Study staff will check in with participants every 4 months to ask if they have any falls and any fractures.


Eligibility

Not Available


Where can I participate?

Beverly


What is the full name of this clinical trial?

Trial Of Parkinson's And Zoledronic Acid

Study Details
Disease Type/Condition

Movement Disorders

Principal Investigator

Bordelon, Yvette

Co-Investigators

Echo Tan, Elliot Hogg

Age Group

Adult

Phase

N/A

IRB Number

STUDY00003282


How do I learn more about this study?
Email
clinicaltrials@cshs.org
Study Detail
Disease Type/Condition

Movement Disorders

Principal Investigator

Bordelon, Yvette

Age Group

Adult

Phase

N/A

IRB Number

NIS-TOPAZ


Contact
Email
clinicaltrials@cshs.org